The R&D day will feature presentations by internal ProQR and external speakers on the progress of the ophthalmology pipeline, including an update on the progress of sepofarsen (formerly named QR-110) for LCA10 and QR-421a for Usher syndrome and discussion of the next therapies to enter the clinic. Speakers will discuss state of the art in research relevant to current and upcoming areas of the company’s pipeline, including the role oligonucleotide therapies will play in accelerating the translation of molecular insights into approved therapies for areas of high unmet medical need.
R&D Day Event Details
The event will be held on
The live and archived webcast of the presentation will be accessible from the Investor Relations section of ProQR’s website (www.proqr.com) under Events and Presentations. The archived webcast will be available for 90 days following the presentation date.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions, including statements regarding the progress of our development and plans for our product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the
Vice President of Investor Relations and Corporate Communications
T: +1 202 360 4855
LifeSci Public Relations
T: +1 646 876 4933
Source: ProQR Therapeutics N.V.